Cytocom, Inc.
CBLI · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $44 |
| % Growth | – | -100% | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $44 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $52 | $118 | $185 | $118 |
| G&A Expenses | $618 | $433 | $592 | $699 |
| SG&A Expenses | $618 | $433 | $592 | $699 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $669 | $551 | $777 | $817 |
| Operating Income | -$669 | -$551 | -$777 | -$773 |
| % Margin | – | – | -295,476,949,289,196.9% | -1,771.3% |
| Other Income/Exp. Net | $10 | $17 | $158 | $46 |
| Pre-Tax Income | -$667 | -$534 | -$619 | -$727 |
| Tax Expense | $2 | $4 | $75 | $18 |
| Net Income | -$660 | -$538 | -$695 | -$745 |
| % Margin | – | – | -264,202,751,937,689.7% | -1,707.8% |
| EPS | -0.043 | -0.038 | -0.053 | -0.057 |
| % Growth | -12.7% | 29.2% | 6.8% | – |
| EPS Diluted | -0.043 | -0.038 | -0.053 | -0.057 |
| Weighted Avg Shares Out | 15,479 | 14,227 | 13,002 | 13,002 |
| Weighted Avg Shares Out Dil | 15,479 | 14,227 | 13,002 | 13,002 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $3 |
| Depreciation & Amortization | $1 | $2 | $3 | $3 |
| EBITDA | -$668 | -$536 | -$692 | -$752 |
| % Margin | – | – | -263,193,403,868,533.7% | -1,723.6% |